Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis

STUART H RALSTON,1 LINDA HACKING,2 LORNA WILLOCKS,1 FIONA BRUCE,1 AND DENIS A PITKEATHLY1

From the 1Medical Unit A and the 2Department of Radiology, Southern General Hospital, Glasgow

SUMMARY A placebo controlled, double blind study of aminohydroxypropylidene bisphosphonate (APD), given by monthly intravenous infusion, was conducted in 40 patients with rheumatoid arthritis. Biochemical markers of increased bone resorption, such as fasting urinary calcium/creatinine ratio and hydroxyproline/creatinine ratio, were suppressed significantly in the APD group to approximately 50% and 60% of the pretreatment level respectively, and serum calcium fell transiently after the first APD infusion. There was no significant effect on disease activity in either the APD or placebo groups as judged by clinical (grip strength, morning stiffness, visual analogue score) or laboratory (haemoglobin, platelet count, erythrocyte sedimentation rate, C reactive protein) criteria. An exception was the articular index which improved to a similar degree in both groups, falling from (mean (SEM)) 13-8 (1-8) to 7-2 (2-2) in the APD group and from 13-7 (1-9) to 6-8 (1-5) in the placebo group. Radiological progression occurred to a similar degree in both groups as assessed by the Sharp index (mean (SEM) 86 (13-1) v 95 (12-9)—APD group; 103 (15-1) v 110 (15-8)—placebo group), but there was no significant change in the Larsen index in either group (mean (SEM)) 53 (4-2) v 57 (3-8)—APD; 62 (5-8) v 63 (5-6)—placebo). The lack of effect on radiological progression in the APD group indicates that focal erosive disease may either have progressed as the result of a non-osteoclast related mechanism, or that the intensity of bone resorption was too great to be inhibited by the doses of APD used. The biochemical response to APD presumably reflected inhibition of bone resorption at other sites, suggesting that further studies of the effects of bisphosphates on periarticular and systemic osteoporosis in rheumatoid arthritis may be of interest.

Key word: osteoporosis.

Periarticular osteoporosis, bone erosions, and generalised osteoporosis are important features of rheumatoid arthritis.1 2 Current management of bone involvement in rheumatoid arthritis is unsatisfactory as disease modifying antirheumatic drugs seldom prevent progression of periarticular erosive disease3 and do not protect against the development of generalised osteoporosis.4 Bisphosphonates, such as aminohydroxypropylidene bisphosphonate (APD), have been shown to be effective in inhibiting accelerated bone resorption in Paget’s disease,5 hypercalcaemia of malignancy,6 primary hyperparathyroidism,7 steroid induced osteoporosis,8 and metastatic cancer.9 We have now studied the clinical, biochemical, and radiographic effects of APD in patients with rheumatoid arthritis.

Patients and methods

It was decided to limit the study to patients with rheumatoid arthritis who were already stabilised by treatment with one disease modifying antirheumatic drug (penicillamine) plus or minus their usual treatment of non-steroidal anti-inflammatory drugs and analgesics. Forty such patients were recruited...
from the general rheumatology clinic on a consecutive basis. All gave informed consent to participation in the study, which was also approved by the local hospital ethical committee. The patients were randomly allocated on a double blind basis to receive monthly intravenous infusions of either APD 30 mg in 500 ml 0-9% saline or a matching placebo, which were given over a two hour period on a day patient basis.

Biochemical and haematological measurements were made on blood and second voided 'spot' urine samples obtained after an overnight fast at each clinic attendance using standard automated techniques. Urinary calcium and hydroxyproline excretion were expressed as molar ratios relative to urinary creatinine. Serum calcium was adjusted for albumin as previously described. Erythrocyte sedimentation rate was determined by the Westergren method.

Clinical assessment was carried out by the same observer (SHR) in each patient monthly for the first three months, at six months, and again at 12 months. The following measures of disease activity in rheumatoid arthritis were recorded: grip strength (dominant hand; mean of three readings), Ritchie articular index, and early morning stiffness. The patients' subjective assessment of joint pain and stiffness was recorded on a visual analogue scale (from 0=no joint pain or stiffness whatsoever to 10=joint pain and stiffness as bad as they could be).

At each clinic visit patients were specifically asked about any adverse effects experienced since the previous visit. Radiological progression of joint disease was assessed on paired radiographs obtained immediately before starting treatment and again after 12 months. These were assessed by a radiologist

---

**Table 1** Relevant clinical and laboratory variables in the study group. Values are mean (SEM)

<table>
<thead>
<tr>
<th>Variable</th>
<th>APD* (n=20)</th>
<th>Placebo (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60 (2-1)</td>
<td>56 (2-7)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>7/13</td>
<td>7/13</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6-9 (1-2)</td>
<td>6-5 (0-8)</td>
</tr>
<tr>
<td>Penicillamine dose (mg/day)</td>
<td>537 (45)</td>
<td>562 (59)</td>
</tr>
<tr>
<td>Duration of penicillamine treatment (months)</td>
<td>34 (5-5)</td>
<td>31 (6-0)</td>
</tr>
<tr>
<td>Haemoglobin (g/l)†</td>
<td>132 (21)</td>
<td>127 (33)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mmol/h)†</td>
<td>38 (5)</td>
<td>44 (8)</td>
</tr>
<tr>
<td>C reactive protein (mg/l)†</td>
<td>27 (10)</td>
<td>33 (9)</td>
</tr>
<tr>
<td>Serum creatinine (μmol/l)†</td>
<td>78 (4-8)</td>
<td>73-5 (4-3)</td>
</tr>
<tr>
<td>Serum alkaline phosphatase (U/l)†</td>
<td>225 (12-2)</td>
<td>224 (15-0)</td>
</tr>
<tr>
<td>Articular index</td>
<td>13-8 (1-8)</td>
<td>13-7 (1-9)</td>
</tr>
<tr>
<td>Grip strength (mm)</td>
<td>101 (14)</td>
<td>92 (10)</td>
</tr>
<tr>
<td>Morning stiffness (min)</td>
<td>61 (14)</td>
<td>51 (10)</td>
</tr>
</tbody>
</table>

*APD=aminohydroxypropylidene bisphosphonate.
†Normal reference ranges: haemoglobin 115-175 g/l; erythrocyte sedimentation rate <30 mm/h; C reactive protein <10 mg/l; serum creatinine 40-130 μmol/l; serum alkaline phosphatase 70-350 U/l.

---

**Fig. 1** Response of serum adjusted calcium values to treatment with aminohydroxypropylidene bisphosphonate (APD) and placebo. Points are means, bars are standard errors of the mean. Reference range 2-20-2-60 mmol/l (not indicated on figures for reasons of clarity). ***p<0.001 from baseline; ○ p<0.01 between groups.

**Fig. 2** Response of fasting urinary calcium/creatinine (Ca/Cr) ratio to treatment with aminohydroxypropylidene bisphosphonate (APD) and placebo. Reference range (mmol/mmol) <0.50. Points are means, bars SEM. ***p<0.001 from baseline; ○ p<0.01 between groups; ◆ p<0.001 between groups.
ist who was unaware of the patient's treatment (LH) and scored using the methods of Larsen et al\(^{12}\) and Sharp et al.\(^{13}\)

The paired and unpaired Student's \(t\) tests were used in statistical analysis of the data. Two tailed probabilities were used throughout.

Results

Table 1 shows the relevant clinical and laboratory variables in the study group. The two treatment groups were closely matched for disease activity as judged by clinical and laboratory criteria, age and sex distribution, disease duration, and penicillamine dose. There were no significant changes in any of the variables shown in Table 1 during the study, with the exception of articular index, which fell from (mean (SEM)) 13.8 (1.8) to 7.2 (2.2) in the APD group and from 13.7 (1.9) to 6.8 (1.5) in the placebo group (both significant; \(p<0.001\)).

In the APD group there was a transient fall in serum calcium one week after the initial infusion, though by one month calcium values had returned to the pretreatment concentration and remained stable thereafter throughout the study period. Serum calcium did not change significantly in the placebo group (Fig. 1).

Urinary calcium/creatinine fell significantly in the APD group from day 7 and remained suppressed throughout the study period. There were no significant changes in calcium/creatinine values in the placebo group (Fig. 2).

Urinary hydroxyproline/creatinine values also fell in the APD group, the change being statistically significant from one month onward. There was no change in hydroxyproline/creatinine values in the placebo group (Fig. 3).

The degree of radiological joint damage, as assessed by the methods of Larsen et al\(^{12}\) and Sharp et al\(^{13}\) was similar in both treatment groups at the beginning of the study. After 12 months radiological progression was noted in both groups using the Sharp method, whereas there was no significant change in the Larsen scores (Table 2).

No side effects directly attributable to the APD were observed during the study, though progression of pre-existing pulmonary fibrosis was noted at six months in one patient treated with APD. This patient was an elderly man of 73, who withdrew from the study after two APD doses because of lack of benefit and the inconvenience of having to attend for monthly intravenous infusions. At the time of withdrawal there was no clinical suspicion of progressive pulmonary disease. Transient flu-like symptoms were observed in two patients treated with APD after the first infusion, but similar symptoms also occurred in three patients treated with placebo.

![Fig. 3 Response of fasting urinary hydroxyproline/creatinine (OH/Cre) ratio to treatment with (APD) and placebo. Reference range (\(\mu\)mol/mmol) >30. Points are means, bars SEM. **\(p<0.01\) from baseline; \(p<0.01\) between groups.](http://ard.bmj.com/)

### Table 2 Effects on radiological progression. Values are mean (SEM) and (range)

<table>
<thead>
<tr>
<th></th>
<th>APD†</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before treatment</td>
<td>After treatment</td>
</tr>
<tr>
<td>Sharp index</td>
<td>86 (13-1) (14-193)</td>
<td>95 (12-9)* (22-203)</td>
</tr>
<tr>
<td>Larsen index</td>
<td>53 (4-2) (26-82)</td>
<td>57 (3-8) (28-85)</td>
</tr>
</tbody>
</table>

*\(p<0.01\) from before treatment; **\(p<0.02\) from before treatment.
†APD = aminohydroxypropylidene bisphosphonate.

In the placebo group 19 pairs of radiographs were available for assessment before and after the study. In the APD group the three patients who dropped out before six months were excluded from analysis, but x rays were analysed from one patient who dropped out after eight months of APD, giving a total of 17 paired radiographs analysed.
Aminohydroxypropylidene bisphosphonate treatment in RA

Discussion

In the present study a single 30 mg infusion of APD had a prolonged inhibitory effect on bone resorption as shown by the significant reduction in both calcium/creatinine and hydroxyproline/creatinine ratios for up to 30 days. These findings concur with previous data in other clinical situations.5–9 Although the fall in hydroxyproline/creatinine ratio was less consistent than that of the calcium/creatinine ratio, this was probably owing to hydroxyproline release from sources other than bone.14

Despite the above biochemical response hand radiographs before and after 12 months showed no significant effect of APD progression of periarticular bone erosions. It is possible that the focal bone resorption associated with these lesions may either have been non-osteoclast mediated,15 and therefore resistant to the effects of APD, or have been too intense to be modified by the doses of APD used in the present study. In either event this focal bone resorption presumably contributed little to the sum total of bone resorptive activity going on throughout the skeleton. Thus the biochemical response probably reflected inhibition of bone resorption associated with more diffuse periarticular osteoporosis or even generalised osteoporosis, which appears to be more prevalent in rheumatoid arthritis.17 The standard radiological methods used to assess progression of erosive disease in this study would not have been sensitive enough to detect such changes in bone density. In future studies it would be interesting to obtain formal measurements of bone mineral content either in the spine or at the distal radius in patients undergoing bisphosphonate treatment.18

APD and other amino substituted bisphosphonates are known to cause flu like symptoms and a transient acute phase response in some individuals, particularly on initial administration, which may be due to stimulation of interleukin 1 release.19 Although such an effect could theoretically worsen rheumatoid arthritis and actually enhance bone resorption, patients treated with APD did not generally experience clinical symptoms consistent with such an effect, or show any greater an acute phase response than those treated with placebo. Indeed, APD treatment was well tolerated generally and had no detectable effect on disease activity.

In view of the biochemical evidence of an inhibitory effect on bone resorption, APD and similar bisphosphonates may be of value in the prevention and management of osteopenia associated with rheumatoid arthritis. Further studies are necessary both to define the precise effects on peripheral and axial bone density and to assess whether or not a different dose regimen or administra-

tion at an earlier stage in the disease could modify progression of periarticular erosive disease.

We thank Ciba Geigy Pharmaceuticals for kindly donating the APD (CGP 23339), and Mrs Dorothy McKnight for help with the statistical analysis.

References

Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis.
S H Ralston, L Hacking, L Willocks, F Bruce and D A Pitkeathly

Ann Rheum Dis 1989 48: 396-399
doi: 10.1136/ard.48.5.396

Updated information and services can be found at:
http://ard.bmj.com/content/48/5/396

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/